opr.-inakt. 1-Acetyl-2-ethyl-cyclopropan | 823-12-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: opr.-inakt. 1-Acetyl-2-ethyl-cyclopropan
• 英文别名: 1-(2-Ethylcyclopropyl)ethanone
• CAS: 823-12-1
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: OSSWVCMXIDMRMO-UHFFFAOYSA-N

物化性质

• 沸点：
  151.0±8.0 °C(Predicted)
• 密度：
  0.918±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  opr.-inakt. 1-Acetyl-2-ethyl-cyclopropan 、 原甲酸三乙酯 在 lead(IV) acetate 、 高氯酸 作用下， 以47%的产率得到ethyl (2-ethylcyclopropyl)acetate
  参考文献：
  名称：

  Nongkhlaw, Rishan Lang; Nongrum, Ridaphun; Nongkynrih, Irona, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 5, p. 1054 - 1057

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-环氧丁烷 、 丙酮基膦酸二乙酯 生成 opr.-inakt. 1-Acetyl-2-ethyl-cyclopropan
  参考文献：
  名称：

  Sturtz,G., Bulletin de la Societe Chimique de France, 1964, p. 2349 - 2357

  摘要：

  DOI：

文献信息

• Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals
  申请人：STROBEL Harmut

  公开号：US20080167342A1

  公开（公告）日：2008-07-10

  The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及以下公式I的N-烷基酰胺，其中A、Het、X、R1、R2和R3具有声明中指出的含义，这些化合物调节内皮型一氧化氮(NO)合酶的转录，并是有价值的药理活性化合物。具体而言，公式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或规范降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制药组合物，以及使用公式I化合物制造用于刺激内皮型NO合酶表达或用于治疗各种疾病，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏衰竭等的药物的用途。
• Amine Derivatives as Potassium Channel Blockers
  申请人：Bionomics Limited

  公开号：US20150299184A1

  公开（公告）日：2015-10-22

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及有用于调节细胞中钾通道活性的化合物，特别是用于调节T细胞中发现的Kv1.3通道活性。本发明还涉及使用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，包含这些化合物的制药组合物和它们的制备方法。
• [EN] DRUG-ELUTING STENTS COATED WITH NON-NUCLEOTIDE P2Y12 RECEPTOR ANTAGONIST COMPOUND<br/>[FR] STENTS POUR ÉLUTION DE MÉDICAMENT AVEC COMPOSÉ ANTAGONISTE RÉCEPTEUR P2Y12 NON NUCLÉOTIDE
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2007056217A2

  公开（公告）日：2007-05-18

  [EN] This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The present invention also provides a drug-eluting stent, wherein the stent is coated with one or more non-mucleotide P2Y₁₂ receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged blood vessel, a therapeutically effective amount of the P2Y₁₂ receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y₁₂ receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting thrombus formation, inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
  [FR] La présente invention concerne un procédé de prévention ou de traitement de maladies ou de conditions associées à l'agrégation de plaquettes. La présente invention porte également sur un stent pour élution de médicament, le stent étant revêtu d'un ou de plusieurs composés antagonistes récepteurs P2Y₁₂ non nucléotides ou d'un sel, solvate, ou hydrate pharmaceutiquement acceptable de ceux-ci. Lorsque le stent est placé dans un vaisseau sanguin rétréci ou endommagé, une quantité thérapeutiquement efficace du composé antagoniste récepteur P2Y₁₂ est éluée en continu entre le stent et l'environnement local du stent. Les stents pour élution de composé antagoniste récepteur P2Y₁₂ servent à la prévention de la thrombose et de la resténose, et sont efficaces pour inhiber la formation de thrombus, inhiber la contraction de cellules musculaires lisses vasculaires, inhiber la prolifération cellulaire, et réduire l'inflammation.
• Sturtz,G., Bulletin de la Societe Chimique de France, 1964, p. 2349 - 2357
  作者：Sturtz,G.

  DOI：——

  日期：——
• Nongkhlaw, Rishan Lang; Nongrum, Ridaphun; Nongkynrih, Irona, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 5, p. 1054 - 1057
  作者：Nongkhlaw, Rishan Lang、Nongrum, Ridaphun、Nongkynrih, Irona、Vattakunnel, Felix Mathew、Myrboh, Bekington

  DOI：——

  日期：——